To determine if ADAM10 plays a role in modulating similar pathways in other tumour types, we also used CRISPR/Cas9-deletion of ADAM10 in the SW620 CRC cell line, since, as described above, ADAM10 is upregulated in GI cancers, associated with stem-cell maintenance, and SW620 cells share stem cell-like characteristics with U251 cells [38,39]. The gene discussed is ADAM10; the disease is colorectal carcinoma.